Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.

Autor: Skowronski DM; BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada.; University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada., Febriani Y; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada., Ouakki M; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada., Setayeshgar S; BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada., El Adam S; BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada., Zou M; BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada., Talbot D; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada., Prystajecky N; BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada.; University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada., Tyson JR; BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada., Gilca R; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada., Brousseau N; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada., Deceuninck G; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada., Galanis E; BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada.; University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada., Fjell CD; BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada., Sbihi H; University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada.; BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada., Fortin E; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada.; Université de Montréal, Département de Microbiologie, Infectiologie et Immunologie, Montreal, Quebec, Canada., Barkati S; McGill University, Department of Medicine, Division of Infectious Diseases, McGill University Health Center, Montreal, Quebec, Canada., Sauvageau C; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada., Naus M; BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada.; University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada., Patrick DM; BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada.; University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada., Henry B; University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada.; Office of the Provincial Health Officer, Ministry of Health, Victoria, British Columbia, Canada., Hoang LMN; BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada.; University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada., De Wals P; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada., Garenc C; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada., Carignan A; Sherbrooke University, Department of Microbiology and Infectious Diseases, Sherbrooke, Quebec, Canada., Drolet M; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada., Jassem AN; BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada.; University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada., Sadarangani M; BC Children's Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada.; University of British Columbia, Department of Pediatrics, Vancouver, British Columbia, Canada., Brisson M; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada., Krajden M; BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada.; University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada., De Serres G; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.; Institut National de Sante Publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada.; Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Nov 30; Vol. 75 (11), pp. 1980-1992.

Urine biomarkers of renal renin-angiotensin system activity: Exploratory analysis in humans with and without obstructive sleep apnea.

Autor: Hanly PJ; Department of Medicine, University of Calgary, Calgary, AB, Canada.; Sleep Centre, Foothills Medical Centre, Calgary, AB, Canada.; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada., Ahmed S; Department of Medicine, University of Calgary, Calgary, AB, Canada.; Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada.; Alberta Kidney Disease Network, Canada., Fjell CD; True Bay Technologies Inc, British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, Canada., Handley GB; Healthy Heart Sleep Company, Calgary, AB, Canada., Sola D; Department of Medicine, University of Calgary, Calgary, AB, Canada.; Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada., Nicholl D; Department of Medicine, University of Calgary, Calgary, AB, Canada.; Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada., Zalucky A; Department of Medicine, University of Calgary, Calgary, AB, Canada.; Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada.

Publikováno v: Physiological reports [Physiol Rep] 2020 Mar; Vol. 8 (6), pp. e14376.

In Vivo, In Vitro, and In Silico Characterization of Peptoids as Antimicrobial Agents.

Autor: Czyzewski AM; Department of Chemical and Biological Engineering, Northwestern University, 2145 Sheridan Road, E136, Evanston, IL, 60208, United States of America., Jenssen H; Centre for Microbial Diseases and Immunity Research, #232-2259 Lower Mall Research Station, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.; Dept. of Science, Systems & Models, Roskilde University, Universitetsvej 1, DK-4000, Roskilde, Denmark., Fjell CD; Centre for Microbial Diseases and Immunity Research, #232-2259 Lower Mall Research Station, University of British Columbia, Vancouver, BC V6T 1Z4, Canada., Waldbrook M; Centre for Microbial Diseases and Immunity Research, #232-2259 Lower Mall Research Station, University of British Columbia, Vancouver, BC V6T 1Z4, Canada., Chongsiriwatana NP; Department of Chemical and Biological Engineering, Northwestern University, 2145 Sheridan Road, E136, Evanston, IL, 60208, United States of America., Yuen E; Centre for Microbial Diseases and Immunity Research, #232-2259 Lower Mall Research Station, University of British Columbia, Vancouver, BC V6T 1Z4, Canada., Hancock RE; Centre for Microbial Diseases and Immunity Research, #232-2259 Lower Mall Research Station, University of British Columbia, Vancouver, BC V6T 1Z4, Canada., Barron AE; Department of Chemical and Biological Engineering, Northwestern University, 2145 Sheridan Road, E136, Evanston, IL, 60208, United States of America.

Publikováno v: PloS one [PLoS One] 2016 Feb 05; Vol. 11 (2), pp. e0135961. Date of Electronic Publication: 2016 Feb 05 (Print Publication: 2016).

Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.

Autor: Boyd JH; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, B.C., Canada., Fjell CD, Russell JA, Sirounis D, Cirstea MS, Walley KR

Publikováno v: Journal of innate immunity [J Innate Immun] 2016; Vol. 8 (2), pp. 211-20. Date of Electronic Publication: 2016 Jan 13.